JS207 Combination Therapy in Triple-negative Breast Cancer

This is an open-label, multi-center, phase II clinical study to preliminarily evaluate the efficacy and safety of JS207 combined with 9MW2821 or albumin paclitaxel as first-line therapy in patients with recurrent or metastatic TNBC.

Trial Details

NCT ID
NCT07045311
Phase
PHASE2
Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • JS207 in combination with 9MW2821
  • JS207 in combination with Albumin paclitaxel
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Baoding, Hebei, China|38.87288,115.46246

Key Eligibility Criteria

  • Male or female age 18 - 75 years old；
  • Voluntary participation in clinical study；
  • Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression);
  • No prior systemic antitumor therapy for locally advanced or Metastatic TNBC；

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →